Dayvigo(lemborexant) Instructions:Uses,Dosage, Side Effects

Lemborexant is a novel dual orexin receptor antagonist developed and manufactured by Eisai, a Japanese pharmaceutical company, specifically for the treatment of insomnia characterized by difficulties with sleep onset or sleep maintenance. The drug competitively binds to orexin receptors OX1R and OX2R, inhibits the wake-promoting effect of orexins, thereby reducing arousal signals, increasing sleepiness, and helping patients restore normal sleep rhythms. 

Since its approval by the U.S. FDA for marketing in December 2019, Lemborexant has been successively approved in dozens of countries and regions, including Japan, Canada, Australia, and China Hong Kong, bringing new treatment options for insomnia patients worldwide. On May 27, 2025, Eisai announced that the marketing application for Lemborexant tablets had been approved by the National Medical Products Administration (NMPA) of China.